ELTX
ELTX clinical trials: Elicio Therapeutics, Inc.
Every trial on ClinicalTrials.gov where Elicio Therapeutics, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 3
- As lead sponsor
- 1
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
ELTX on the catalyst calendar · ELTX registry changes
- Primary completion Not registeredNo phase registeredNCT07083479Expanded Access Protocol of ELI-002-102 in Subjects With KRAS/NRAS Mutated Pancreatic Ductal AdenocarcinomaElicio Therapeutics · Pancreatic Ductal AdenocarcinomaNo longer availableELTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Apr 20, 2026ActualPhase 1/Phase 2NCT05726864A Study of ELI-002 7P in Subjects With KRAS/NRAS Mutated Solid TumorsElicio Therapeutics · Pancreatic Ductal AdenocarcinomaActive, not recruitingELTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 26, 2023ActualPhase 1NCT04853017A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid TumorsElicio Therapeutics · Minimal Residual DiseaseCompletedELTXLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2028Sponsor estimatePhase 1NCT07671339A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic CancerMemorial Sloan Kettering Cancer Center · Pancreatic CancerRecruitingELTXCollaboratorONCCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner